No difference was observed between mice treated with 24-4C01 as wild-type IgG2a versus Fc-D265A mutation. human monoclonal antibody response to influenza in the context of vaccines. == INTRODUCTION == Influenza epidemics result in 250,000500,000 deaths annually (World Health Business, 2014). Vaccination offers the most effective protection against contamination but vaccines have to be reformulated every year due to antigenic drift. (Krammer and Palese, 2015). In addition to seasonal epidemics, influenza computer virus strains that are antigenically divergent can arise, leading sporadically to pandemics. The surface glycoprotein hemagglutinin (HA) is the main target of neutralizing antibodies (Kaur et al., 2011). Seasonal vaccination generally induces a thin, strain-specific response against the highly variable head domain name of HA, whereas broadly neutralizing antibodies specific to the more conserved stalk domain name are typically rare (Henry Dunand et al., 2015;Krammer and Palese, 2013;Wilson and Andrews, 2012). Althoughin vitroneutralization traditionally correlates with protection against contamination in humans (Couch and Kasel, 1983), recent work has highlighted the importance of non-neutralizing antibodies (Jegaskanda et al., 2013a;Krammer et al., 2014b;Terajima et al., 2015). A more complete understanding of all types of protective antibodies is critical for the improvement of existing influenza vaccines and the development of new ones. A novel reassortant avian H7N9 computer virus crossed the species barrier and caused a zoonotic epidemic in China in 2013 (Gao et al., 2013;Watanabe et al., 2013). This computer virus reemerged in 2014 and 2015 in a seasonal pattern, causing morbidity and mortality in humans (World Health Business, 2015). Although computer virus transmission occurs primarily through poultry exposure, its continuous blood circulation in poultry and the large number of sporadic human infections increase the chance of a new reassortment or the acquisition of mutations that could switch the properties of the computer virus (Hu et al., 2014). To prevent H7N9 influenza infections, a live-attenuated A/Anhui/1/2013 H7N9 computer virus vaccine candidate was developed (Chen et al., 2014b) and evaluated in healthy individuals (Sobhanie et al., 2015). Induction of potent humoral immune responses with H7 vaccines has proven to be problematic due to the poor immunogenicity of novel avian HAs (Cox et al., 2009). Several studies using inactivated or live attenuated H7 vaccines (Couch et al., 2012;Cox et al., 2009;Karron et al., 2009;Rudenko et al., 2014;Talaat et al., 2009;Treanor et al., 2006) showed similarly modest results. However, an H7N7 live-attenuated computer virus vaccine led to long-term cross-reactive immune memory (Babu et al., 2014) and a strong recall response with high-affinity H7 head and stalk domain-specific serum antibodies (Halliley et al., 2015). Given that candidate H7N9 vaccines are currently being developed, it is vital to assess if protective antibodies are induced following vaccination, and additionally, to characterize the diversity of epitopes targeted around the HA protein. In this study, we mapped the H7 HA antigenic sites using human monoclonal antibodies (mAbs) isolated from individuals who experienced received an H7N9 vaccine. Pirinixil Twelve mAbs with particularly high potency and/or breadth of reactivity to multiple influenza strains were chosen for in-depth characterization. These mAbs bound to numerous epitopes on the head and the stalk domains and were found to be both neutralizing and non-neutralizingin vitro. Importantly, passive transfer of both categories of mAbs guarded micein vivoagainst a stringent lethal challenge. Pirinixil This work identifies potential therapeutic mAbs and provides a better understanding of the antibody response to H7 viruses. == RESULTS == == Generation and characterization of human monoclonal antibodies after H7N9 immunization == Four healthy individuals were primed with either one or two doses of a live attenuated cold-adapted influenza A/Anhui/1/2013 (H7N9) vaccine (Chen et al., 2014b). The subjects were then boosted 12 weeks later with an inactivated computer virus vaccine based on the closely related A/Shanghai/2/2013 (H7N9) strain (Sanofi Pasteur) (Physique 1A). Plasmablasts were isolated 7 days after administration of the inactivated vaccine and mAbs were cloned as previously explained (Smith et al., 2009;Wrammert et al., 2008). Twenty mAbs bound A/Anhui/1/2013 (H7N9) HA by ELISA and were then CCNE2 screened using three criteria: HAI activity, neutralization activity, and cross-reactivity to diverse influenza A HAs (group 1 and group 2). Nine out of the 20 mAbs displayed neutralization activity, with 6 displaying HAI activity (Physique 1B). Half of the mAbs (10/20) were cross-reactive within group 2 HAs (H3 and H7) and/or between group 1 and 2 HAs (Physique 1B). Twelve influenza virus-positive mAbs with particularly high potency (HAI and microneutralization) and/or breadth were then chosen for full characterization: 22-3E05, Pirinixil 07-5B05, 07-5D03, 07-4D05, 07-5F01, 07-5G01,.